Rational quinidine dosage regimen for atrial fibrillation in Thoroughbred racehorses based on population pharmacokinetics.
Authors: Kuroda Taisuke, Minamijima Yohei, Kinman Christopher Ken, Takahashi Yuji, Ebisuda Yusaku, Inoue Kaori, Ishikawa Hiroshi, Mita Hiroshi, Tamura Norihisa, Nukada Toshio, Toutain Pierre-Louis, Ohta Minoru
Journal: Frontiers in veterinary science
Summary
# Editorial Summary: Rational Quinidine Dosing for Equine Atrial Fibrillation Atrial fibrillation remains a significant concern in Thoroughbred racehorses, and whilst quinidine sulfate is established as an effective antiarrhythmic agent, considerable individual variation in drug response and safety margins has created clinical uncertainty around optimal dosing. Kuroda and colleagues employed population pharmacokinetic modelling—analysing plasma quinidine concentrations across multiple treated horses—to characterise this variability and derive evidence-based dosage recommendations tailored to Thoroughbreds. The population pharmacokinetic approach identified key factors influencing drug clearance and distribution, enabling the researchers to propose a rational dosing regimen that maximises efficacy whilst minimising the risk of adverse effects including cinchonism and cardiotoxicity. For equine practitioners managing AF cases, this work provides a pharmacologically grounded framework for individualising quinidine therapy rather than relying on historical or empirical protocols, ultimately improving treatment outcomes and safety margins. The findings underscore the value of population pharmacokinetics in optimising antimicrobial and antiarrhythmic therapy in equine medicine, where traditional one-size-fits-all dosing frequently produces suboptimal results.
Read the full abstract on PubMed
Practical Takeaways
- •Quinidine dosing should be individualized based on population pharmacokinetic parameters rather than using one-size-fits-all regimens to improve treatment outcomes and safety
- •Understanding inter-individual variability in drug metabolism helps predict which horses may require dose adjustments to avoid therapeutic failure or toxicity
- •This pharmacokinetic approach provides a scientific foundation for optimizing quinidine therapy in racehorses with atrial fibrillation
Key Findings
- •Population pharmacokinetic analysis identified substantial inter-individual variability in quinidine plasma concentrations in Thoroughbred racehorses with atrial fibrillation
- •Rational dosage regimen based on population pharmacokinetics developed to optimize quinidine efficacy while minimizing adverse effects
- •Study addresses the wide variability in treatment response to quinidine sulfate in equine atrial fibrillation cases